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Abstract
We report the results from a phase I study of buparlisib, an oral pan-class I phosphotidyinositol-3-
kinase inhibitor, combined with capecitabine in patients with metastatic breast cancer. The 
maximum tolerated dose of the combination was buparlisib 100 mg daily and capecitabine 1000 
mg/m2 twice daily. A complete response was seen in 1 patient with a basal-like tumor. 
Pharmacokinetic analysis suggested that a pharmacokinetic interaction might exist between the 2 
agents.
Background—Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. 
The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with 
capecitabine in patients with metastatic breast cancer.
Patients and Methods—Patients received buparlisib once daily (range, 50 to 100 mg) for 3 
weeks with capecitabine twice daily (range, 1000 to 1250 mg/m2) for 2 weeks with a 1-week 
break. Dose escalation used a traditional “3 + 3” design with standard definitions of dose-limiting 
toxicity (DLT) and maximum tolerated dose.
Results—Of the 25 patients enrolled, 23 were evaluable for DLT and 17 were evaluable for 
response. The maximum tolerated dose of the combination was buparlisib 100 mg daily and 
capecitabine 1000 mg/m2 twice daily. DLTs included grade 3 hyperglycemia and grade 3 
confusion. The most common grade 3 toxicities were diarrhea and elevation of aspartate 
aminotransferase and alanine transaminase. One patient exhibited a complete response to 
treatment and four had a confirmed partial response. In cohorts 3 and 4, in which the buparlisib 
dose remained constant but the capecitabine dose was increased, significant increases in the 
buparlisib plasma concentration were noted.
Conclusion—The combination of buparlisib with capecitabine in patients with metastatic breast 
cancer was generally well-tolerated, with several patients demonstrating prolonged responses. 
Unexpectedly low rates of PIK3CA mutations (3 of 17) were seen, and only 2 of 7 tumors with 
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subtyping were luminal, making exploration of these putative predictive markers impossible. 
Further study of the combination is not unreasonable, with expanded pharmacokinetics and 
sequencing analysis to better elucidate potential drug–drug interactions and more accurate 
predictive biomarkers of response.
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Introduction
Constitutive activation of the phosphatidylinositol-3-kinase (PI3K) pathway has been 
observed in a variety of human malignancies, including breast cancer, in which PIK3CA 
mutations are the most common genetic abnormality.1 Molecular changes can include (1) 
gain-of-function mutations encoding positive regulators of PI3K; (2) loss-of-function 
mutations affecting negative regulators (eg, PTEN); and (3) mutations of genes encoding 
downstream effectors.2 Thus, pathway-mutated tumors might be particularly sensitive to 
treatment with PI3K inhibitors.
Physicians have long observed considerable heterogeneity in the prognosis and behavior of 
breast cancer. The results from gene expression profiling studies have supported this 
heterogeneity and underscore the importance of developing more effective treatment 
strategies for advanced disease by the identification of driver mutations or pathway 
addiction.3 It has become increasingly clear that gene expression profiling can be used to 
more accurately classify and predict the behavior of breast cancer. Using DNA microarray 
technology, Sorlie et al4 have identified and validated 5 major subtypes of breast tumors, 
including basal-like, HER2 overexpressing, luminal-like (including luminal A and B), and 
normal breast tissue-like. Somatic mutation rates of PIK3CA vary according to molecular 
subtype, with luminal-like (A and B), HER2-enriched, and basal-like harboring 45%, 29%, 
39%, and 9%, respectively.1
Luminal B subtype tumors represent 10% to 18% of human breast cancer cases and have a 
poor prognosis relative to other estrogen receptor-positive (ER+) breast cancers, with 
significantly lower survival in both locally advanced and early-stage settings.5 Creighton et 
al,6 who developed a genetic signature comprehensively examining the PI3K pathway in 
hormone receptor-positive breast cancer, found a high correlation between their signature 
and the luminal B subtype with a worse prognosis. PIK3CA mutations have also been 
detected at a high rate in HER2-enriched tumors and are thought to contribute to resistance 
to HER2 targeted therapies.7 Knowing the intrinsic subtype of a patient’s tumor might, 
therefore, provide a better selection process for patients who might benefit from PI3K 
targeted therapy.
Buparlisib is an oral pan-class I PI3K inhibitor that targets the catalytic subunits encoded by 
the PI3KCA gene. The first in-human phase I trial of buparlisib in patients with advanced 
refractory solid tumors established the maximum tolerated dose (MTD) of buparlisib to be 
100 mg daily.8 The most frequent adverse events (AEs) in that study were decreased 
appetite, nausea, constipation, diarrhea, fatigue, rash, and hyperglycemia. Subsequent 
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randomized studies of buparlisib plus the selective ER downregulator fulvestrant for patients 
with advanced breast cancer (BELLE-2 [buparlisib plus fulvestrant vs. placebo plus 
fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast 
cancer] and BELLE-3 [a phase III study of BKM120 with fulvestrant in patients with HR+ 
(hormone receptor positive), HER2−, AI (aromatase inhibitor) treated, locally advanced or 
metastatic breast cancer who progressed on or after mTORi (mammalian target of rapamycin 
inhibitor)]) have been reported, with modest improvements in progression-free survival 
(PFS) for the combination compared with hormonal therapy alone.9,10 Other clinical trials 
evaluating the safety of buparlisib combined with chemotherapy (including paclitaxel as a 
single agent and carboplatin plus paclitaxel) have recently been reported.11,12
Capecitabine is an oral fluoropyrimidine that was approved in 1998 for the treatment of 
metastatic breast cancer. Capecitabine is among the preferred single agents recommended by 
the National Comprehensive Cancer Network Oncology Practice Guidelines for treatment of 
metastatic breast cancer and has also demonstrated safety and activity combined with 
biologic agents, including trastuzumab, lapatinib, and bevacizumab.13–15 As a single agent, 
capecitabine has demonstrated efficacy and a favorable side effect profile.16,17 In the present 
trial, we evaluated capecitabine combined with buparlisib in a phase I trial of patients with 
metastatic breast cancer to determine the safety, dose-limiting toxicity (DLT), and MTD of 
the combination. Our rationale was that this all-oral regimen, if tolerable, might be an 
attractive and effective therapy, especially for patients with luminal B breast cancer 
refractory to endocrine therapy, and could be further tested in that subgroup. Exploratory 
analyses aimed at evaluating the differential response to treatment according to intrinsic 
molecular subtypes and PIK3CA mutational analysis were performed.
Patients and Methods
Patient Eligibility
Patients with a histologic diagnosis of metastatic breast cancer for which capecitabine was 
deemed a reasonable treatment option were eligible for enrollment. The eligibility criteria 
also included age ≥ 18 years, Eastern Cooperative Oncology Group performance status of 0 
to 2, and life expectancy of ≥ 12 weeks. The patients were required to have either 
measurable or nonmeasurable, but evaluable, disease as defined using Response Evaluation 
Criteria In Solid Tumors, version 1.1. Normal bone marrow function was defined as follows: 
absolute neutrophil count ≥ 1500/µL, platelet count ≥ 100,000/µL, and hemoglobin ≥ 8.5 
g/dL. Organ function was required to be within normal limits, with the following caveats: 
total bilirubin ≤ 1.5 times the upper limit of normal and aspartate aminotransferase (AST)/
alanine transaminase (ALT) ≤ 3 times the upper limit of normal, if liver metastases were 
present. The fasting plasma glucose level was required to be < 120 mg/dL. The patients had 
to have recovered from all toxicities related to their previous treatment (other than alopecia) 
to grade ≤ 1 or baseline. Brain metastases were allowed if central nervous system-directed 
treatment had been given ≥ 3 months before enrollment with clinically and radiographically 
stable disease for ≥ 8 weeks.
The pertinent exclusion criteria included previous treatment with capecitabine or a PI3K 
inhibitor; concurrent use of an endocrine, a cytotoxic, or a biologic agent; major surgery ≤ 2 
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weeks before starting buparlisib; and chronic systemic treatment with steroids or other 
immunosuppressive agents. Patients with known dihydropyrimidine dehydrogenase 
deficiency were excluded, as were patients with known coagulopathies resulting from 
warfarin-derived anticoagulant agents. Other comorbid conditions that prohibited enrollment 
included acute or chronic liver disease, renal disease, pancreatitis, poorly controlled diabetes 
mellitus, a known diagnosis of human immunodeficiency virus infection, inadequately 
controlled hypertension, and clinically significant active cardiac disease. Patients with 
documented mood or anxiety disorders and those with gastrointestinal dysfunction resulting 
in impaired absorption were also excluded.
The institutional review board of the University of North Carolina at Chapel Hill approved 
the present study. It was registered with the US National Institutes of Health 
(ClinicalTrials.gov identifier, NCT01300962). All patients provided written informed 
consent before the initiation of any study-related procedures or treatments.
Treatment Plan
The present study was designed as a phase I trial to establish the safety, tolerability, and 
MTD of buparlisib combined with capecitabine in patients with metastatic breast cancer. 
The primary objective was to determine the DLT and MTD of the combination. The 
secondary objectives included characterizing the acute and chronic toxicities. As exploratory 
objectives, the pharmacokinetic (PK) profile of buparlisib with capecitabine was evaluated, 
and predictive biomarkers were correlated with the therapeutic response. The study 
consisted of 4 cohorts, outlined in Table 1. The patients received oral buparlisib at a starting 
dose of 50 mg once daily for 3 weeks combined with a starting dose of capecitabine at 1000 
mg/m2 twice daily for 2 weeks followed by a 1-week break. The patients were instructed per 
protocol to take their morning dose of capecitabine at the same time as their daily dose of 
buparlisib 1 hour after a light breakfast. Any patient who received treatment in accordance 
with the protocol was evaluable for toxicity. Patients not experiencing DLTs were required to 
complete ≥ 1 cycle of therapy (3 weeks) to be evaluable for the MTD determination. Any 
patient who withdrew from study before day 14 of cycle 1 without experiencing a DLT was 
replaced.
The study used a traditional “3 + 3” design. If none of the initial 3 patients enrolled 
experienced a DLT within the first 3 weeks, the subsequent cohort of patients was treated at 
the next dose level. If 1 of the 3 patients in any cohort experienced a DLT, 3 additional 
patients were enrolled into that same cohort. If only 1 of these 6 patients experienced DLT, 
subsequent patients were enrolled into the next cohort. If ≥ 2 of these 6 patients experienced 
a DLT, or 2 patients experienced a DLT in a cohort of 3 patients, the MTD was considered to 
have been exceeded. If 2 patients experienced a DLT in a cohort of 3 patients, 3 additional 
patients were assigned to the lower dose level, unless 6 patients had already been enrolled at 
that dose level, or if this had occurred in cohort 1.
Assessments
Toxicity Assessment and Definition of DLT—AEs and DLTs were defined using the 
National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. The 
McRee et al. Page 4













following were considered DLTs if they occurred with the first cycle of therapy (3 weeks) 
and were considered possibly related to study treatment: (1) any intolerable grade ≥ 2 
nonhematologic or grade 3 hematologic toxicity that required withholding a dose for > 7 
days or required a dose reduction; (2) any grade ≥ 4 hematologic toxicity; (3) other grade ≥ 
3 nonhematologic toxicity (except for alopecia and nausea, vomiting, and diarrhea unless 
persistent for > 48 hours despite maximum supportive care); (4) grade ≥ 2 photosensitivity; 
and (4) ≥ 1 grade level increase in neurotoxicity. The MTD was defined as the highest dose 
at which ≤ 1 of 6 patients experienced a DLT. No intra-patient dose escalation was allowed.
PK Assessments—PK sampling was performed in cycle 1 on days 1 and 8 and in cycle 2 
on day 1 (day 22 of treatment). A 3-mL blood sample was collected immediately before 
capecitabine administration and 2 hours after buparlisib administration on each day. The 
buparlisib plasma concentration was measured using a validated liquid chromatography–
tandem mass spectrometry assay with a lower limit of quantification of 1 ng/mL.8 Buparlisib 
plasma concentrations were summarized at each measurement point.
PIK3CA Mutational Analysis—Mutational analysis for hotspot mutations within the 
PIK3CA gene was performed using Sanger dideoxy-sequencing of PIK3CA exons 9 and 20. 
After enrichment for tumor cells by macrodissection, genomic DNA was extracted from 
formalin-fixed paraffin-embedded (FFPE) slides and subjected to Sanger dideoxy-cycle 
sequencing using primers homologous to the relevant regions.
Gene Expression Profiling—RNA was extracted from archived, FFPE tumor samples 
(High Pure FFPE Kit; Roche Diagnostics, Indianapolis, IN). Nanostring analyses were 
performed at the Rapid Adoption Molecular Laboratory at the University of North Carolina. 
Nanostring probe sets included 110 genes, of which 50 were the PAM50 genes and 5 were 
housekeeping genes, as described previously.5 In brief, 100 ng of each purified total RNA 
was labeled with molecular barcodes representing genes. The labeled molecules were 
counted using the Nanostring nCounter (Nanostring Technologies, Seattle, WA) as gene 
expression raw data. Raw data was log base 2 transformed and normalized using positive 
controls and 5 housekeeping transcripts and then median centered along with 150 training 
data (from the 9830 nano110 project). All samples, including 150 training samples, were 
standardized to a 0 mean and unit variance. The PAM50 intrinsic subtype and claudin-low 
predictors were used to assign an intrinsic subtype (luminal A, luminal B, HER2-enriched, 
basal-like, and normal-like) to each tumor sample.5 Gene expression and clinical data were 
deposited in the Gene Expression Omnibus.
Clinical and Response Assessment—The baseline evaluations at enrollment included 
a history and physical examination, performance status determination, baseline laboratory 
measurements, a 12-lead electrocardiogram, an echocardiogram, and imaging studies to 
assess the tumor measurements. Patients were required to complete both the patient health 
questionnaire-9 (PHQ-9) and the generalized anxiety disorder 7-item (GAD-7) scale as a 
measure of mood and anxiety level. The medical history and focused physical examination 
were repeated on the first day of each cycle. Toxicity assessments were gathered weekly 
(days 1, 8, and 15) during cycle 1 and then on day 1 of the subsequent cycles. The tumor 
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A total of 25 breast cancer patients were enrolled at 2 institutions. The patient demographic 
data and baseline disease characteristics are summarized in Table 2. The median age of the 
women in the study was 50 years (range, 26 to 65 years). Most patients were white. A total 
of 10 patients had tumors that were ER+. Only 1 patient’s tumor was HER2 overexpressing. 
The remaining 15 patients had triple negative breast cancer (TNBC). The sites of metastatic 
disease included nodal/soft tissue in 11 patients, lung in 10 patients, bone in 8 patients, and 
liver in 7 patients. The median number of previous treatments was 2 (range, 0 to 6).
DLT and Determination of MTD
Of the 25 patients who received treatment in the study, 2 patients (1 in cohort 1 and 1 in 
cohort 3) were deemed not evaluable for DLT assessment because they did not receive an 
entire cycle of therapy (both because of rapid disease progression). The DLTs associated 
with buparlisib and capecitabine are summarized in Table 1. In all 4 cohorts, the first 3 
evaluable patients enrolled in each treatment arm did not experience DLT. Therefore, a 
planned expansion of cohort 4 was initiated, with 1 patient of 5 experiencing a DLT of grade 
3 confusion. Additionally, 4 of the 5 patients in this cohort experienced grade ≥ 3 toxicity 
during cycle 2 of treatment consisting of fatigue, photosensitivity/pruritus, rash, anxiety/
hallucinations, mania, psychosis, depression, and concentration impairment. Given the 
cumulative toxicity in cohort 4, further enrollment to that cohort was halted, and an 
expansion of cohort 3 was conducted. Of the 13 total patients enrolled in cohort 3, 1 DLT 
was observed (grade 3 hyperglycemia); hence, the MTD was determined to be the dose 
given to cohort 3, consisting of buparlisib 100 mg once daily combined with capecitabine 
1000 mg/m2 twice daily.
Adverse Events
All patients enrolled in the trial reported ≥ 1 treatment-related AE, with 13 patients (52%) 
experiencing grade ≥ 3 toxicity. The most common AEs of all grades associated with 
buparlisib and capecitabine were nausea (56%), hand-foot syndrome (HFS; 52%), mucositis 
(48%), diarrhea (40%), and rash (including photosensitivity; 36%; Table 3). The most 
common grade ≥ 3 toxicities were diarrhea and grade 3 elevation of AST and ALT (both 
presenting in 3 patients each). Other grade 3 toxicities included HFS and rash (occurring in 
2 patients each), with the remaining 7 grade 3 and 4 AEs occurring in 1 patient each. A total 
of 10 patients (40%) experienced ≥ 1 AE related to psychiatric impairment, mood, memory, 
or cognition; 2 in cohort 1, 4 in cohort 3, and 4 in cohort 4. One patient experienced multiple 
grade 3 AEs (concentration impairment, confusion, and depression), and one reported grade 
4 toxicities (anxiety, hallucinations, mania, and psychosis). Both patients had been treated in 
cohort 4, with the symptoms predominantly occurring in cycle 2 of treatment. The most 
common AEs resulting in dose delays included rash (including photosensitivity and 
pruritus), HFS, hyperglycemia, diarrhea, mood impairment, mucositis, and fatigue.
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At baseline and throughout the study, the patients completed both the PHQ-9 and the GAD-7 
surveys. The mean highest PHQ-9 values for each dose level were 4, 6, 4, and 9. The mean 
highest GAD-7 values for each dose level were 3, 3, 4, and 7. Of these, only 3 patients had a 
score clinically suggestive of depression (> 10 on the PHQ-9) and 4 patients had a score 
suggestive of clinically relevant anxiety (> 10 on the GAD-7). All of these occurred in 
cohorts 3 and 4. The 2 patients in cohort 4 with the highest scores for both surveys also 
experienced grade 3 toxicity that included anxiety, hallucinations, depression, and impaired 
concentration.
Tumor Response and Clinical Benefit
Of the 25 patients who received treatment in the trial, 17 were evaluable for response. The 
median number of cycles received for all patients was 4 (range, 2 to 32). One patient in 
cohort 3 with heavily pretreated TNBC and lung metastases exhibited a complete response 
after receiving 11 cycles of treatment. She received a total of 32 cycles and discontinued 
because of mood changes that resolved with withdrawal of therapy. Four patients (2 ER+, 1 
HER2+, and 1 TNBC) experienced a partial response to treatment, with a maximum 
percentage of change from baseline ranging from 34% to 67%. The remaining evaluable 
patients (4 ER+ and 8 TNBC) demonstrated stable disease, 3 of whom continued with 
treatment for ≥ 6 months. Of all 25 patients enrolled in the trial, 7 patients had died at study 
completion, none within 28 days of receiving treatment and all attributed to disease 
progression.
Pharmacokinetics
The mean buparlisib plasma concentrations in each cohort on days 1, 8, and 22 of treatment 
are summarized in Table 4. With no PK data collected for buparlisib alone for each patient, 
the potential PK interactions between buparlisib and capecitabine were evaluated by (1) 
comparing differences in the PK of buparlisib at increasing doses (50, 80, and 100 mg) 
combined with a constant dose of capecitabine (1000 mg/m2); and (2) comparing differences 
in the PK of buparlisib at the same dose (100 mg) combined with varying doses of 
capecitabine (1000 and 1250 mg/m2). In cohorts 1, 2, and 3, all of whom had received the 
same dose of capecitabine (1000 mg/m2), an inconsistent increase in buparlisib 
concentrations at 2 hours after buparlisib on days 8 and 22. These results raise the possibility 
that a PK interaction might exist between buparlisib and capecitabine, because the exposure 
of buparlisib increased at a much greater extent at 100 mg compared with buparlisib at 80 
mg with a constant dose of capecitabine.
The buparlisib plasma concentrations on days 1, 8, and 22 collected before and 2 hours after 
buparlisib administration in cohorts 3 and 4 are presented in Figure 1. These patients all 
received a buparlisib dose of 100 mg daily. The higher dose of capecitabine in cohort 4 
(1250 mg/m2) was associated with greater exposure of buparlisib on all days compared with 
the dose of capecitabine in cohort 3 (1000 mg/m2). On day 8, a statistically significant 
increase was found in the buparlisib concentrations collected 2 hours after administration in 
cohort 4 (1390 ± 300 ng/mL) compared with cohort 3 (728 ± 249 ng/mL; P = .049; Table 4). 
Similarly, a statistically significant increase in buparlisib concentrations was detected on day 
22 (2 hours after administration) in cohort 4 (1386 ± 135 ng/mL) compared with cohort 3 
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(1004 ± 317 ng/mL; P = .014; Table 4). These results suggest that the higher dose of 
capecitabine in cohort 4 (1250 mg/m2) compared with that in cohort 3 (1000 mg/m2) 
increased the exposure of buparlisib, despite a constant dose of buparlisib (100 mg).
PIK3CA Mutational Analysis
A total of 21 patients had archived tissue available for PIK3CA mutational analysis. Of 
those, 4 had insufficient DNA quantity for testing. Of the remaining 17 samples, 3 contained 
an activating mutation in PIK3CA (2 in exon 20 and 1 in exon 9). The presence of an 
activating mutation did not appear to correlate with a greater likelihood of response to 
buparlisib. Of the 3 mutated tumors, 1 patient demonstrated progressive disease during cycle 
2 and died approximately 1 month after discontinuing treatment. The remaining 2 patients 
had stable disease (nonmeasurable but evaluable) but discontinued treatment during the trial 
at the onset of cycle 3 because of toxicity.
Gene Expression Profiling
FFPE tumor samples were available from 14 patients, of which 7 had sufficient RNA for 
Nanostring analysis. Intrinsic molecular subtyping revealed 4 basal-like (57%), 1 luminal A 
(14%), 1 luminal B (14%), and 1 normal-like tumor (14%). The patient who had 
experienced a complete response to treatment, continuing therapy for 32 cycles, had a tumor 
with a basal-like subtype. Two patients with a partial response (continuing therapy for 5 and 
15 cycles) had tumors with luminal B and luminal A subtypes, respectively. The small 
sample size and the scant number of tumors with analyzable RNA made this analysis 
exploratory, because we lacked power for any significant correlations with response or 
survival.
Discussion
The present study is a phase I trial of the oral PI3K inhibitor buparlisib combined with 
capecitabine in patients with metastatic breast cancer. The MTD of the combination was 
determined to be buparlisib 100 mg daily combined with capecitabine 1000 mg/m2 twice 
daily. This dose of buparlisib is consistent with the MTD reported in the first-in-human 
phase I trial of single-agent buparlisib.8 The DLT associated with buparlisib and 
capecitabine in our study included grade 3 hyperglycemia and confusion. Approximately 
one half of patients in the study experienced grade ≥ 3 toxicity. The most common AEs were 
diarrhea, AST and ALT elevation, HFS, and rash. The median treatment time was 12 weeks, 
with 1 patient demonstrating a complete response.
We evaluated for potential PK interactions between buparlisib and capecitabine by 
comparing both the differences in PK of buparlisib at increasing doses (50, 80, and 100 mg) 
combined with a constant dose of capecitabine (1000 mg/m2) and the differences in the PK 
of buparlisib at the same dose (100 mg) combined with increasing doses of capecitabine 
(1000 and 1250 mg/m2). We observed an inconsistent increase in buparlisib concentrations 
on days 8 and 22 collected 2 hours after buparlisib administration (Table 4). These results 
suggest that a PK interaction between buparlisib and capecitabine might exist, because the 
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exposure of buparlisib did not demonstrate a linear increase, despite a constant dose of 
capecitabine.
Additionally, at a constant 100-mg dose of buparlisib, increased exposure of buparlisib was 
documented, with the higher dose of capecitabine administered in cohort 4 (1250 mg/m2) 
compared with the lower dose of capecitabine in cohort 3 (1000 mg/m2; Figure 1). This was 
a statistically significant difference on days 8 and 22 between cohorts 3 and 4 (P = .049; 
Table 4). These results suggest that the higher dose of capecitabine in cohort 4 (1250 
mg/m2) compared with the dose in cohort 3 (1000 mg/m2) increased the exposure of 
buparlisib, perhaps by altering the absorption and/or the metabolism of buparlisib. However, 
the metabolism pathways of the 2 drugs are not especially overlapping to explain the 
potential drug–drug interactions. Preclinical data showed buparlisib to be a sensitive 
CYP3A4 substrate, an enzyme that has insignificant bearing on capecitabine metabolism. 
This finding has not been reported in studies of capecitabine combined with other oral 
targeted agents, including everolimus, sunitinib, and sorafenib, all of which have 
demonstrated no PK interactions.18–20 A phase I study reported by our group of buparlisib 
combined with mFOLFOX6 (modified leucovorin calcium, 5-fluorouracil, oxaliplatin) 
reported an increased incidence of grade 3 and 4 toxicity with the combination than would 
be expected from either the PI3K inhibitor or the chemotherapy agent alone.21 In that study, 
the MTD of buparlisib combined with mFOLFOX6 was only 40 mg, which, we believe, 
suggests a potential interaction between 5-fluorouracil derivatives and PI3K inhibitors.
The Tumor Genome Atlas (TCGA) Network reported that PIK3CA mutations are present in 
as many as 45% of breast cancer cases across all subtypes; hence, PI3K inhibitors represent 
an attractive treatment strategy for metastatic patients.1 An observational study of 90 
patients with a variety of advanced tumor types reported that PIK3CA-mutated cancers 
(specifically in exon 20) demonstrated greater response rates to PI3K/AKT/mTOR inhibitors 
compared with wild-type tumors treated with their best phase I option.22 Only 3 patients in 
our study had tumors with activating mutations in PIK3CA (2 in exon 20), which precluded 
a meaningful association with response to buparlisib. Other potential biomarkers of response 
have been reported, including aberrations in PTEN, AKT, and INPP4B, which were not 
evaluated in our study. Additionally, the coexistence of other pathway mutations with 
PIK3CA mutations might increase the risk of resistance to PI3K inhibitors. For example, in 
a review of 66 PIK3CA-mutant tumors treated with PI3K/AKT/mTOR pathway inhibitors, 
none of the 16 patients with concomitant KRAS mutations demonstrated a response to 
therapy.23 Therefore, understanding in more depth how the tumor kinome adjusts to PI3K 
pathway inhibition might provide additional preclinical data for how to best combine 
buparlisib with other targeted agents in future clinical trials.
A total of 7 patients had tumors with sufficient RNA for Nanostring analysis to determine 
the intrinsic molecular subtype. Of these, basal-like tumors were found in 4 patients, luminal 
subtypes in 2 patients (1 A and 1 B), and normal breast tissue-like in 1 patient. The 2 
luminal tumors did not harbor PIK3CA mutations in our study despite the greater reported 
incidence in this subtype. However, of the basal-like tumors, 1 patient achieved a complete 
response to treatment (with no evidence of an activating PIK3CA mutation). Although basal-
like tumors typically have lower rates of PIK3CA mutations (7%), TCGA breast cancer data 
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reported a greater incidence of PTEN mutations or loss (35%) in basal-like tumors than in 
other subtypes.1 Basal-like tumors also demonstrated widespread genomic instability with 
increased copy number/ amplification of many downstream components of the PI3K and 
RAS-RAF-MEK pathway, including PIK3CA (49%), BRAF (30%), and EGFR (23%). 
These features might have contributed to the robust response of the basal-like tumor to 
buparlisib in our study. However, the small sample size of our study and the inability to 
determine whether patients’ clinical benefit was driven by the capecitabine itself limited any 
meaningful evaluation of the molecular subsets.
In addition to our study, buparlisib has been studied in combination with other agents, 
mostly hormonal therapies in breast cancer patients with ER+ tumors. The BELLE-2 trial, a 
large randomized phase III trial of 1147 patients with advanced hormone-positive breast 
cancer, randomized patients to fulvestrant either alone or combined with buparlisib.24 All 
patients in that trial had previously been treated with aromatase inhibitors and had developed 
progression. The investigators reported a statistically significant improvement in PFS with 
fulvestrant plus buparlisib of 6.9 months compared with 5.0 months with fulvestrant alone. 
A planned exploratory analysis of clinical outcomes in those patients with PIK3CA 
mutations detected in circulating tumor DNA revealed a significant difference in PFS in the 
buparlisib-treated patients versus placebo but not in those lacking a mutation. The same 
randomization of fulvestrant as a single agent or combined with buparlisib was applied to 
the BELLE-3 trial with 432 postmenopausal breast cancer patients enrolled with previous 
disease progression with both an aromatase inhibitor and an mTOR inhibitor.9 An 
improvement in PFS from 1.8 to 3.9 months was reported, suggesting that resistance to the 
mTOR pathway could be overcome by targeting PI3K. Again, the improvement in PFS was 
more pronounced for patients with mutant PIK3CA genes. Although these results provide 
further rationale for targeting the PI3K pathway in breast cancer, many concerns were raised 
regarding the toxicity of this combination, most notably the mood disturbances and suicidal 
ideation. Biologically, this can be attributed to the ability of small molecules to cross the 
blood–brain barrier, with future emphasis on developing isoform-specific PI3K inhibitors 
that target mutant variations of the protein only.
Two studies have combined buparlisib with trastuzumab (1 of which also contained 
paclitaxel) for patients with HER2+ breast cancer with progression during trastuzumab-
based therapies.25,26 The combination was well tolerated, and in both studies, the MTD of 
buparlisib was 100 mg daily. Although both were small studies, the promising disease 
control rates seen in this refractory population did lend credence to the hypothesis that 
inhibiting the PI3K pathway might reverse resistance to HER2 targeted therapies. Lapatinib, 
a dual anti-HER2/EGFR tyrosine kinase inhibitor, is approved in combination with 
capecitabine in patients with HER2+ breast cancer and has also been studied in combination 
with buparlisib. However, a phase I study of buparlisib and lapatinib that enrolled 24 patients 
with refractory HER2+ breast cancer reported increased toxicity with 5 patients experiencing 
DLTs in the first cycle of treatment.27 No evidence was found of a PK drug–drug 
interaction. The recommended phase 2 dose of buparlisib was therefore reported as 80 mg 
daily with 1000 mg of lapatinib. In an unpublished cohort of our study, HER2+ patients 
received buparlisib combined with capecitabine and lapatinib. In the first cohort of 4 
patients, buparlisib was administered at 60 mg daily for 21 days with lapatinib 750 mg daily 
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and 1000 mg/m2 of capecitabine twice daily for 14 days. Within 1 cycle, one half of the 
patients experienced DLT; therefore, treatment was discontinued. This occurred although all 
3 drugs were administered at doses less than the recommended phase 2 dose, which begs the 
question regarding whether dual inhibition of HER2 and EGFR in conjunction with PI3K 
inhibition leads to increased toxicity.
Conclusion
The present phase I trial of the oral PI3K inhibitor buparlisib plus capecitabine in patients 
with metastatic breast cancer found the combination to be generally well tolerated, with 
several patients demonstrating prolonged responses. Similar to other larger studies of 
buparlisib in breast cancer patients, psychiatric effects of buparlisib were observed in our 
study, with 20% of patients reporting mood disturbances but with limited grade 3/4 toxicity. 
The MTD of the combination was 100 mg of buparlisib daily combined with capecitabine 
1000 mg/m2 twice daily. The PK analysis suggested the possibility of a drug–drug 
interaction with a statistically significant increase in buparlisib concentrations at higher 
capecitabine doses. Unexpectedly low rates of PIK3CA mutations (3 of 21) were observed, 
and only 2 of 7 tumors with subtyping available were luminal, resulting in a limited 
exploration of these predictive markers. One patient with a basal-like tumor experienced a 
complete response during the study. The basal-like tumor is a subtype reported to have 
increased amplification of many components of the PI3KandRAS-RAF-MEKpathways. 
Further study of the combination of buparlisib with chemotherapeutic agents, although not 
unreasonable, should be pursued with caution to minimize toxicity and, ideally, will involve 
more definitive correlative studies to better predict those patients who would be more likely 
to respond to PI3K inhibitors to avoid undue toxicity.
Clinical Practice Points
• PIK3CA mutations are the most common genetic abnormality in breast cancer; 
hence, PI3K inhibitors represent an attractive treatment strategy for advanced 
breast cancer patients.
• Buparlisib is an oral pan-class I PI3K inhibitor that has been studied in 
combination with both hormonal therapies and chemotherapeutic agents, 
showing safety and some efficacy.
• Capecitabine is an oral fluoropyrimidine and is among the preferred single 
agents for treatment of metastatic breast cancer.
• In our phase I study of buparlisib plus capecitabine in patients with metastatic 
breast cancer, the MTD of the combination was buparlisib 100 mg daily and 
capecitabine 1000 mg/m2 twice daily.
• The DLTs associated with buparlisib and capecitabine in our study included 
grade 3 hyperglycemia and confusion; the most common AEs were diarrhea, 
AST and ALT elevation, HFS, and rash.
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• The PK analysis showed a statistically significant increase in buparlisib 
concentrations at higher capecitabine doses, suggesting a potential drug–drug 
interaction.
• The only complete response during the study was in 1 patient with a basal-like 
tumor; no association was seen between the presence of PIK3CA mutations and 
the response to buparlisib.
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Buparlisib Plasma Concentrations Collected on Days 1, 8, and 22 (Before and 2 Hours After 
Buparlisib Administration) Displayed From Patients in Cohorts 3 and 4. These Patients 
(Each Represented With a Different Symbol) Received the Same Dose of Buparlisib (100 
mg Daily) but With Increasing Doses of Capecitabine (1000 mg/m2 and 1250 mg/m2, 
Respectively). Mean Values for Each Time Point Are Represented by the Black Horizontal 
Line. Despite the Same Administered Dose of Buparlisib, the Higher Dose of Capecitabine 
in Cohort 4 Was Associated With Higher Buparlisib Exposure. This Was Statistically 
Significant 2 Hours After Buparlisib on Both Days 8 and 22
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Table 2
Patient Characteristics (n = 25)
Characteristic Value
Age (y)
  Median 50
  Range 26–65
Race
  White 22
  Black 3
Tumor subtype
  ER− PR− HER2− (TNBC) 15
  ER+ 10
  HER2+ 1
Metastatic site
  Nodal/soft tissue 11
  Lung 10
  Bone 8
  Liver 7
Previous treatments
  Median 2
  Range 0–6
Abbreviations: ER = estrogen receptor; PR = progesterone receptor.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Clin Breast Cancer. Author manuscript; available in PMC 2019 August 01.
